智通财经APP讯，恒瑞医药(01276)公布，近日,公司的HRS-4642注射液被国家药品监督管理局药品审评 中心纳入突破性治疗品种名单。本品联合吉西他滨和紫杉醇(白蛋白结合型)用于携带KRAS G12D突变 的晚期或转移性胰腺癌的一线治疗。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年2月6日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 证券代码：600276 证券简称：恒瑞医药 公告编号：临2026-023 ...

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting advanced or metastatic pancreatic cancer with KRAS G12D mutation [1] Group 1: Product Development - HRS-4642 is a self-developed KRAS G12D inhibitor in a liposomal formulation [1] - The product is intended for use in combination with gemcitabine and albumin-bound paclitaxel as a first-line treatment [1] - Currently, there are no similar drugs approved for market domestically or internationally [1] Group 2: Market Context - Pancreatic cancer is a common malignant tumor of the digestive system, with 510,566 new cases reported globally in 2022, ranking 12th among malignant tumors [1] - The disease resulted in 467,005 deaths in 2022, making it the 6th leading cause of cancer-related deaths, accounting for approximately 5% of global cancer mortality [1]

Core Viewpoint - The article highlights the significant acquisitions made by Boyu Capital, including SKP, Badaling Outlet, and Starbucks China, showcasing its strategic positioning in the high-end retail market and its understanding of consumer psychology in China [2][4][11]. Group 1: Acquisitions and Market Position - Boyu Capital has made three major acquisitions in less than a year, including the purchase of SKP, Badaling Outlet, and Starbucks China, indicating its aggressive expansion strategy in the high-end retail sector [2][4][11]. - Badaling Outlet, despite its remote location, has thrived by attracting middle-class consumers looking for discounted luxury goods, with sales reaching 5.2 billion yuan during the 2025 National Day holiday [9][11]. - SKP's sales are projected to decline by approximately 17% in 2024, while Badaling Outlet's revenue has grown from 1.8 billion yuan in its opening year to 2.84 billion yuan in 2024, with a profit of around 900 million yuan [11][19]. Group 2: Consumer Behavior Insights - The article discusses the evolving consumer psychology among the middle class, who desire brand prestige without overspending, which Badaling Outlet effectively capitalizes on by offering luxury items at significant discounts [8][9]. - The outlet's strategy of providing a mix of nearly 300 brands, including high-end labels, has created a win-win situation for both consumers and brands, allowing for inventory clearance while satisfying consumer demand for value [9][11]. Group 3: Company Background and Leadership - Boyu Capital, founded in 2011, is one of China's largest private equity firms, managing approximately $10 billion in funds and boasting a portfolio of over 200 companies [13][14]. - The founding team includes notable figures such as Zhang Zixin, a former executive at Ping An, and Ma Xuezheng, known for her significant contributions to the investment landscape in China [14][15][16]. Group 4: Broader Investment Strategy - Beyond retail, Boyu Capital has diversified its investments into various sectors, including property, technology, and clean energy, indicating a comprehensive approach to capital allocation [17][19]. - The firm has also engaged in significant investments in data centers and biotechnology, reflecting a forward-looking strategy that aligns with future market demands [19].

证券代码：600276 证券简称：恒瑞医药 公告编号：临2026-023 受理号：CXHL2400083 药物类型：化学药品 注册分类：1类 江苏恒瑞医药股份有限公司 关于药物纳入突破性治疗品种名单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日,江苏恒瑞医药股份有限公司（以下简称"公司"）的HRS-4642注射液被 国家药品监督管理局药品审评中心（以下简称"药审中心"）纳入突破性治疗品 种名单。现将相关情况公告如下： 一、药物的基本情况 药物名称：HRS-4642注射液 江苏恒瑞医药股份有限公司董事会 2026 年 2 月 6 日 申请日期：2025年12月24日 拟定适应症（或功能主治）：本品联合吉西他滨和紫杉醇（白蛋白结合型） 用于携带KRAS G12D突变的晚期或转移性胰腺癌的一线治疗。 理由及依据：经审核，本申请符合《药品注册管理办法》和《国家药监局关 于发布＜突破性治疗药物审评工作程序（试行）＞等三个文件的公告》（2020年 第82号）有关要求，同意纳入突破性治疗药物程序。 二、药物的其他相关情况 胰腺 ...

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting first-line treatment for advanced or metastatic pancreatic cancer with KRAS G12D mutation [1] Group 1: Drug Development - The proposed indication for HRS-4642 is in combination with gemcitabine and albumin-bound paclitaxel [1] - The total research and development investment for the related project has reached approximately 254 million yuan [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1]

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting first-line treatment for advanced or metastatic pancreatic cancer with KRAS G12D mutation [1] Group 1: Product Development - HRS-4642 is a liposomal formulation KRAS G12D inhibitor that specifically binds to KRAS G12D, inhibiting the phosphorylation of MEK and ERK proteins to exert anti-tumor effects [1] - The total R&D investment for the related project has reached approximately 254 million yuan [1] Group 2: Regulatory and Market Context - The inclusion in the breakthrough therapy list indicates potential expedited development and approval processes, which may enhance market opportunities for the product [1] - Drug development is subject to various uncertainties related to technology, approval, and policy factors [1]

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the Drug Review Center, aimed at treating advanced or metastatic pancreatic cancer with KRASG12D mutations [1] Group 1: Product Development - HRS-4642 is a Class 1 chemical drug developed by the company, intended for first-line treatment of pancreatic cancer with KRASG12D mutations [1] - The drug is expected to be submitted for approval by December 24, 2025 [1] - The total research and development investment for this project has reached approximately 254 million yuan [1] Group 2: Market Context - There are currently no similar drugs approved for market, both domestically and internationally, indicating a potential competitive advantage for the company [1] - The development of the drug is subject to various factors that may introduce uncertainty risks [1]

Core Viewpoint - The report highlights the premium rates of AH shares, with Northeast Electric, Zhejiang Shibao, and Sinopec Oilfield Services leading in premium rates, while CATL, China Merchants Bank, and WuXi AppTec are at the bottom of the list [1][2][3]. Premium Rate Rankings - The top three AH shares by premium rate are: - Northeast Electric (00042) with a premium rate of 831.03% - Zhejiang Shibao (01057) with a premium rate of 353.97% - Sinopec Oilfield Services (01033) with a premium rate of 302.25% [2] - The bottom three AH shares by premium rate are: - CATL (03750) with a premium rate of -11.84% - China Merchants Bank (03968) with a premium rate of -3.56% - WuXi AppTec (02359) with a premium rate of 1.72% [3] Deviation Value Rankings - The top three shares by deviation value are: - Dazhu CNC (03200) with a deviation value of 60.25% - Muyuan Foods (02714) with a deviation value of 37.19% - Beijing Jingcheng Machinery Electric (00187) with a deviation value of 27.09% [1][4] - The bottom three shares by deviation value are: - Zhejiang Shibao (01057) with a deviation value of -39.99% - Junda Co., Ltd. (02865) with a deviation value of -35.13% - Yangtze Optical Fibre and Cable (06869) with a deviation value of -23.61% [1][5]